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Abstract
Background: Influenza is a common infection among travelers, and attack rates are well documented in short-term
travelers and holiday makers. Little data exists on long-term, non-expatriate travelers.
Methods: This was a prospective mono-centre study of immunocompetent, Dutch travelers aged ≥18 to 64 years.
It was conducted at the Public Health Service travel clinic in Amsterdam from December 2008 to September 2011,
and included all travelers intending to travel to a tropical or sub-tropical country.
Results: Among 602 Dutch long-term travelers to tropical regions, 82 % had protective influenza antibody titres
pre-travel. The influenza attack rate of serologically confirmed infection during travel was 15 %, and of symptomatic
infection was 6.3 % (fever alone) and 2 % (ILI), respectively.
Conclusions: The attack rate in this study is similar to seasonal rates of infection in the general population. Influenza
vaccination pre-travel is therefore most important for people at risk of medical complications due to influenza.
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Background
Influenza is the most frequently reported vaccine-
preventable disease affecting visitors to (sub) tropical
countries [1]. In 2009, an increase in the proportion of
travel-related respiratory disease in Europe, mostly at-
tributable to pandemic A(H1N1) influenza, was recorded
[2]. The impact of influenza virus infection on travelers
in terms of morbidity, healthcare accessed and
hospitalization, is well documented [3] in short-term
holiday makers, business travelers, and other traveler
groups (Hadj pilgrims [4], cruise-ship passengers [5]).
Travelers are also an acknowledged risk for onward
transmission while in transit and at home [6]. Western
adults are traveling in unprecedented numbers to emer-
ging economies (often tropical and subtropical regions),
for prolonged periods for ‘gap years’, to work, study, and
tour. In this study of Dutch long-term travelers (3 to
12 months) to (sub) tropical regions, we prospectively
document the attack rate (AR) of influenza infection and
the incidence of influenza like illness (ILI) while travel-
ing, and identify risk factors associated with symptom-
atic and asymptomatic infection from 2009 to 2011.
Methods
A prospective mono-centre study of immunocompetent,
Dutch travelers aged ≥18 to 64 years was conducted at the
Public Health Service travel clinic in Amsterdam from
December 2008 to September 2011. All clients planning
to travel to any (sub) tropical country in Africa, Central
America, the Caribbean, South America or Asia for ≥12
and ≤52 weeks were invited to participate. Pre-travel, cli-
ents were interviewed by a nurse or physician and asked
about travel purpose (work/study or tourism), travel dur-
ation, planned destination(s), and demographic details. No
influenza vaccination history was established, but in the
Netherlands, influenza vaccination is not recommended
for travelers or healthy, young adults. At the time of the
study, vaccination was only recommended for people ≥
65 years and people with certain chronic diseases. Partici-
pants were given a digital thermometer (Huikeshoven
Medical, Tiel, The Netherlands) and asked to take their
temperature if they felt feverish while traveling. They kept
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a structured, weekly travel diary, recording their itinerary,
symptoms experienced including respiratory, gastrointes-
tinal and other systemic complaints and physician visits
while ill. Diaries were completed on paper or digitally.
Travelers received a weekly email reminder and were seen
2 to 6 weeks after return. Blood samples were taken before
and after travel and paired samples were tested simul-
taneously post-travel for antibodies against influenza vi-
ruses using the hemagglutination-inhibition (HI) assay
[7, 8]. Vaccine strains used represented the epidemic
strains circulating worldwide during the study period:
A(H1N1pdm09), A(H3N2brisbane), A(H3N2perth),
A(H1N1brisbane), B/Florida and B/Brisbane [9]. Influ-
enza infection was defined as a ≥4-fold rise in antibody
titre post-travel from a pre-travel titre of ≥10, or if pre-
travel titer was <10 titer, a post-travel titer of ≥40.
Fever was defined as thermometer-confirmed body
temperature >38.0 °C and influenza like illness (ILI)
was defined as fever and cough or sore throat in the ab-
sence of other diagnoses. Primary regions visited while
travelling were categorized into Influenza Transmission
Zones [10] and then into 4 regions: South East Asia,
Africa, Central and Latin America and “Asia (Other)”
(Fig. 1).
Differences in the proportion of confirmed influenza in-
fections by sex, age-group, primary influenza transmission
zone visited, fever >38.0 °C and ILI were tested using Pear-
son’s chi-squared for each influenza strain. Positive pre-
dictive value (PPV) for seroconversion was the proportion
of symptomatic cases seroconverting for infection. The as-
sociation between infection and ILI was tested using logis-
tic regression and odds ratios with 95 % confidence
intervals. Incidence of fever and ILI while travelling was
estimated as 1st episodes of fever or ILI per 100 person-
weeks of travel with Poisson distributed 95 % confidence
intervals (STATA version 13).
Results
Study population
Overall, 602 respondents were included. The median age
was 25 years (IQR:23–30), and 64 % (n = 389) were fe-
male; median travel duration was 20 weeks (IQR:16–25
weeks). Travelers’ primary destinations (influenza trans-
mission zone) are listed in Table 1. Travel periods were:
228 (38 %) travelled in 2009 (earliest departure: 9
December 2008), 309 (51 %) through 2010, 255 (42 %)
through 2011 and 47 (8 %) through 2012 (latest return
01 September 2012). Pre-travel, 82 % (n = 496) had pro-
tective influenza antibody titres: 214 (36 %) for
A(H1N1pdm09), 264 (44 %) for A(H3N2brisbane), 283
(47 %) for A(H3N2perth), 202 (34 %) for A(H1N1bris-
bane), 208 (35 %) for B/Florida and 68 (11 %) for B/
Fig. 1 Influenza transmission regions and influenza attack rates. Countries where travelers spent the majority of their trip were categorized into
Influenza Transmission Zones and then, for analysis, into 4 regions: South East Asia, Africa, Central and Latin America and “Asia (Other)”
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Table 1 Cross-tabulations of seroconversion for influenza viruses circulating worldwide during the study period for n = 602 long-term Dutch travelers, 2009 to 2012
Variables Total
respondents
N
Seroconversion for
any virusa
A/California/007/09
H1N1pdm [H1pdm09]
A/Brisbane/59/07
[H1N1]
A/Brisbane/10/07
[H3N2]
A/Perth/16/09
[H3N2]
B/Florida/4/06 B/Brisbane/60/08
n n/N% p value n n/N% p value n n/N% p value n n/N% p value n n/N% p value n n/N% p value n n/N% p value
Total 602 90 15 N/A 43 7 N/A 16 3 N/A 26 4 N/A 34 6 N/A 12 2 N/A 11 2 N/A
Age-group
<25 years of age 249 36 14 16 6 5 2 9 4 17 7 4 2 3 1
25–28 years 169 39 23 22 13 7 4 10 6 9 5 5 3 5 3
> = 29 years 184 15 8 <0.001* 5 3 0.001* 4 2 0.366 7 4 0.482 8 4 0.531 3 2 0.571 3 2 0.410
Gender
Female 389 63 16 31 8 12 3 17 4 24 6 5 1 5 1
Male 213 27 13 0.247 12 6 0.287 4 2 0.379 9 4 0.933 10 5 0.454 7 3 0.093 6 3 0.180
Major travel flu zone
Southeast Asia 252 39 15 16 6 3 1 11 4 17 7 5 2 5 2
Central & South America 222 36 16 20 9 10 5 9 4 10 5 5 2 5 2
Asia, other 21 2 10 1 5 0 0 0 0 0 0 1 5 0 0
Africa 107 13 12 0.687 6 6 0.580 3 3 0.132 6 6 0.702 7 7 0.469 1 1 0.679 1 1 0.771
Age was summarized into tertiles: <25 years, 25–28 years and > =29 years. N/A Not Applicable
aIn 10 individuals where the pre-travel titre was ≥40 there was evidence of re-infection (4 fold rise in antibody titre)
P value throughout is Pearson’s chi-squared; Significance assigned (*) at p < 0.01
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Brisbane. Of those who departed before the ‘public
health emergency of international concern’ (pandemic)
was formally declared on 25 April 2009 [11] (n = 107),
22 % were already positive for A(H1N1pdm09) as early
as January 2009. There was no difference in age or gen-
der compared to those who were H1N1pdm09 negative
pre-travel.
Influenza symptoms and infections
Of all 602 travelers, 209 (35 %) had fever while traveling
with a median temperature of 38.5 °C (range 38.0 to
41.4 °C). Five percent (n = 32/602) met the definition for
ILI of whom seven complained of 2 ILI episodes. A fur-
ther n = 149 with fever also complained of headache,
retrosternal pain or myalgia but did not meet the ILI
definition. Of ILI episodes (n = 39), 54 % were accom-
panied by myalgia, 26 % by joint pain, 36 % by diarrhea
and 21 % by vomiting. A doctor’s visit due to ILI was re-
ported in 44 % (14/32) of cases. Diagnostic confirmation
of the cause was not available. The incidence of first epi-
sode of ILI was 0.24 per 100 person-weeks of travel (95
% CI: 0.17-0.34) and of fever >38 °C, 1.6 per 100 person-
weeks (95 % CI:1.4–1.8), similar in early weeks of travel
(i.e. the first 12 weeks) and late travel periods. Any influ-
enza virus infection was serologically confirmed in 38 of
the 209 travelers with fever (PPVfever = 18 %) and 12 of
32 travelers with ILI (PPVILI = 38 %).
Overall, 90 travelers seroconverted (attack rate = 15 %):
n = 53 (9 %) seroconverted for 1 virus only (half were
H1N1pdm09); 26 (4 %) for 2 viruses (16 were for both
H3N2 viruses, two related strains where cross-reactivity
was expected); 7 for 3 viruses and 4 people for 4 viruses.
The only factor associated with any seroconversion was
age (Table 1), and per-virus, only in those who serocon-
verted for H1N1pdm where more seroconversions oc-
curred in those aged 25–28 years (Table 1). Influenza
transmission zone visited was not a significant factor in
seroconversion (Table 1). The AR for symptomatic infec-
tion (fever and ILI) was 6.3 % (38/602) and 2 % (12/602),
respectively. Travelers that seroconverted, particularly to
H1N1pdm09, were more likely to complain of ILI.
(ORref:H1N1pdm09 6.2 [95 % CI:2.6–14.4], Table 2). Serocon-
version to an increasing number of viruses was positively
associated with ILI (IRRunit increase in virus seroconversions: 2.4,
95 % CI:1.5–4.0, p = 0.001). No seasonality (data not
shown) or differences across influenza transmission zones
(Fig. 1) was found with ILI onset or fever >38°.
Discussion
In this young cohort of long-term travelers to (sub) trop-
ical countries (2009 to 2012), the attack rate for con-
firmed influenza virus infection was 15 %. This is higher
than the 1–7 % found in other, mainly short-term trav-
eler studies [1, 12, 13] and closely mirrors seasonal rates
of infection in the (unvaccinated) general population in
temperate [14] and tropical [15] regions during the same
period, reflecting the prolonged travel duration. For
symptomatic infection, we found attack rates of 6.3 %
(fever alone) and 2 % (ILI), respectively, which was
higher than in two short-term studies that found attack
rates of 0.9–1.3 % for confirmed infections with fever
alone [1, 12] and 0.8 % for ILI [12]. The results of symp-
tomatic infections however, should be interpreted with
care. First, some studies use different definitions than
ILI for symptomatic infections and do not report fever
as the only symptom of confirmed infection [13]. Sec-
ond, fever is a very common symptom in travelers [1,
12]. At the same time, confirmed infections without
fever were found in 32 and 83 %, respectively [1, 12]. Be-
cause virological data from nasopharyngeal sampling
was not available for any of the studies, we can not be
sure whether the symptoms were caused by influenza or
by other infections. In our study, both the proportion of
travelers with fever (35 %) and the proportion of trav-
elers with confirmed infections without fever (58 %)
were high. Therefore we did not calculate IR’s for symp-
tomatic influenza infections.
As shown elsewhere [15], travelers in their mid-20s
were more susceptible to A(H1N1pdm09) infection than
other viruses. The majority of respondents were immune
to at least one virus pre-travel, and 1/5th departing be-
fore the pandemic was declared were positive for
A(H1N1pdm09) as early as January 2009. Forty percent
of travelers were infected with >1 virus while traveling
and 10 people experienced a reinfection. Travelers in-
fected with A(H1N1pdm09) during travel were more
likely to be symptomatic with ILI. Overall, the positive
predictive value of ILI was 38 %. We found no evidence
of seasonality or destination-specific risk, and travel was
not a risk factor for severe disease.
There were some limitations to our study. The pre-
travel influenza vaccination status was not confirmed.
However, in the Dutch healthcare system, it is very un-
common that healthy, young travelers are vaccinated.
Table 2 Association between individual virus seroconversion
and influenza like illness (ILI) during the study period
(2009 to 2012)
Virus Odds ratioa 95 % CI p value
A/California/007/09 H1N1pdm 6,2 2.6–14.4 0.000
A/Brisbane/59/07 1,2 0.2–9.3 0.866
A/Brisbane/10/07 3,6 1.1–11.0 0.028
A/Perth/16/09 1,8 0.5–6.2 0.354
B/Florida/4/06 1.0 [−−-] [−−-]
B/Brisbane/60/08 1.0 [−−-] [−−-]
aOdds ratio of association between seroconversion with individual virus and
complaining of ILI. Univariable logistic regression by virus
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Another possible limitation is that travelers only mea-
sured their temperature if they ‘felt feverish’ rather than
daily. This may have lead to an underestimate of the
proportion of travelers with fever, and an overestimate
of the number of asymptomatic infections.
Vaccination for travelers against influenza has been
discussed [16]. In the USA, influenza vaccination is rec-
ommended for all US residents aged ≥6 months [17].
The USA guidelines for international travel (Yellow
Book, 2016) say ‘any traveler who wants to reduce the
risk for influenza infection should consider influenza
vaccination ≥2 weeks before departure if they plan to
travel to the tropics’. According to WHO, influenza vac-
cination should be part of the routine immunization
program for international travelers belonging to a risk
group, in particular during influenza seasons [18].
In the Netherlands, only people at risk for complica-
tions are adviced influenza vaccination. Because there is
no evidence that travel is an additional risk factor for in-
fluenza, the Dutch guidelines for travelers health advice
do not recommend influenza vaccination for travelers
other than those at high risk of complications.
Conclusions
We found that the attack rate of influenza in long-term
travelers closely mirrors seasonal rates in the general
population in temperate and tropical regions and travel
was not a risk factor for severe disease. Influenza vaccin-
ation pre-travel is therefore most important for people
at risk of medical complications due to influenza.
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